HSE has ‘almost exhausted’ its 2019 funding for new drugs

HSE has ‘almost exhausted’ its 2019 funding for new drugs
Professor Michael Barry, who heads up the National Centre for Pharmacoeconomics

Professor Michael Barry, who heads up the National Centre for Pharmacoeconomics (NCPE), was speaking after the HSE informed Biogen, manufacturer of Spinraza, it would not fund the drug

The HSE has “almost exhausted” the available funding it has for new drugs in 2019 just two months into the year, the state’s medicines watchdog has warned.

Please Subscribe or Log in to continue reading

Subscribe Login

Independent journalism every day

With digital access you can read The Business Post whenever, wherever, and however you want.

  • Unlimited access to all sections of The Business Post on desktop, tablet and mobile.
  • Breaking news, comment and analysis from the best Business Post writers seven days a week.
  • Live blogs of major news events.
  • Videos and podcasts from some of the industry's most respected journalists such as Michael Brennan, Susan Mitchell and Ian Guider.
  • Access to The Business Post's extensive archive​.

Related Articles

More from The Business Post